In detail, the PDX tumor harbors a genomic amplification of the MYC gene, missense mutations in TP53 (R158H), and a splice mutation in the RB1 gene, along with mutations in the genes encoding the histone H3K4me1/2 methyl transferase KMT2D (Q3601*)64, the histone acetyltransferase CREBBP (Q935Hfs*63)65, and genomic loss of the gene for the tumor suppressive receptor TNFRSF14/HVEM66. The gene discussed is TNFRSF14; the disease is neoplasm.